Theoretical novel medical isotope production with deuterium-tritium fusion technology

IF 1.8 3区工程技术 Q3 CHEMISTRY, INORGANIC & NUCLEAR

Applied Radiation and Isotopes Pub Date : 2025-09-04 DOI:10.1016/j.apradiso.2025.112163

Lee J. Evitts , Philip W. Miller , Chiara Da Pieve , Andrew Turner , Stefano Borini

{"title":"Theoretical novel medical isotope production with deuterium-tritium fusion technology","authors":"Lee J. Evitts , Philip W. Miller , Chiara Da Pieve , Andrew Turner , Stefano Borini","doi":"10.1016/j.apradiso.2025.112163","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The emergence and growth of fusion technology enables investigative studies into its applications beyond typical power production facilities. This study seeks to determine the viability of medical isotope production with the neutrons produced in an example large fusion device. Using FISPACT-II (a nuclear inventory code) and a simulated fusion spectrum, the production yields of a significant number of potentially clinically relevant (both in use and novel) medical isotopes were calculated. Comparative calculations were also conducted against existing production routes.</div></div><div><h3>Results</h3><div>Depending on the neutron flux of the fusion device, it could be an ideal technology to produce alpha-emitters such as <sup>212</sup>Bi/<sup>212</sup>Pb, it may be able to contribute to the production of <sup>99m</sup>Tc/<sup>99</sup>Mo, and could offer an alternative route in the production a few Auger-emitting candidates. There is also a long list of beta-emitting nuclides where fusion technology may be best placed to produce over existing technologies including <sup>67</sup>Cu, <sup>90</sup>Y and <sup>47</sup>Sc.</div></div><div><h3>Conclusions</h3><div>It is theoretically viable to produce existing and novel medical isotopes with fusion technology. However, a significant number of assumptions form the basis of this study which would need to be studied further for any particular nuclide of interest.</div></div>","PeriodicalId":8096,"journal":{"name":"Applied Radiation and Isotopes","volume":"226 ","pages":"Article 112163"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Radiation and Isotopes","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969804325005081","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The emergence and growth of fusion technology enables investigative studies into its applications beyond typical power production facilities. This study seeks to determine the viability of medical isotope production with the neutrons produced in an example large fusion device. Using FISPACT-II (a nuclear inventory code) and a simulated fusion spectrum, the production yields of a significant number of potentially clinically relevant (both in use and novel) medical isotopes were calculated. Comparative calculations were also conducted against existing production routes.

Results

Depending on the neutron flux of the fusion device, it could be an ideal technology to produce alpha-emitters such as ²¹²Bi/²¹²Pb, it may be able to contribute to the production of ^99mTc/⁹⁹Mo, and could offer an alternative route in the production a few Auger-emitting candidates. There is also a long list of beta-emitting nuclides where fusion technology may be best placed to produce over existing technologies including ⁶⁷Cu, ⁹⁰Y and ⁴⁷Sc.

Conclusions

It is theoretically viable to produce existing and novel medical isotopes with fusion technology. However, a significant number of assumptions form the basis of this study which would need to be studied further for any particular nuclide of interest.

查看原文本刊更多论文

利用氘氚聚变技术生产新型医用同位素

融合技术的出现和发展使得对其应用的调查研究超越了典型的电力生产设施。本研究旨在确定在一个大型核聚变装置中产生的中子生产医用同位素的可行性。利用FISPACT-II（核清单代码）和模拟聚变光谱，计算了大量可能具有临床相关性（包括使用中的和新的）医用同位素的产量。还对现有的生产路线进行了比较计算。结果根据核聚变装置的中子通量，它可能是生产212Bi/212Pb等α -发射体的理想技术，可能有助于99mTc/99Mo的生产，并为生产一些候选的俄热发射体提供了一条替代途径。还有一长串发射β的核素，在这些核素中，核聚变技术可能比现有技术更适合生产，包括67Cu、90Y和47Sc。结论利用核聚变技术生产现有和新型医用同位素在理论上是可行的。然而，对于任何感兴趣的特定核素，需要进一步研究的大量假设构成了这项研究的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Applied Radiation and Isotopes 工程技术-核科学技术

CiteScore

3.00

自引率

12.50%

发文量

406

审稿时长

13.5 months

期刊介绍： Applied Radiation and Isotopes provides a high quality medium for the publication of substantial, original and scientific and technological papers on the development and peaceful application of nuclear, radiation and radionuclide techniques in chemistry, physics, biochemistry, biology, medicine, security, engineering and in the earth, planetary and environmental sciences, all including dosimetry. Nuclear techniques are defined in the broadest sense and both experimental and theoretical papers are welcome. They include the development and use of α- and β-particles, X-rays and γ-rays, neutrons and other nuclear particles and radiations from all sources, including radionuclides, synchrotron sources, cyclotrons and reactors and from the natural environment. The journal aims to publish papers with significance to an international audience, containing substantial novelty and scientific impact. The Editors reserve the rights to reject, with or without external review, papers that do not meet these criteria. Papers dealing with radiation processing, i.e., where radiation is used to bring about a biological, chemical or physical change in a material, should be directed to our sister journal Radiation Physics and Chemistry.